ACTL6A在宫颈癌中的表达及意义

目的:探讨ACTL6A在宫颈癌中的表达及意义。方法:收集2012年1月至2015年1月间我院收治的93例宫颈癌患者的癌组织和癌旁组织石蜡标本,采用免疫组化法测定ACTL6A表达情况,分析其与临床病理参数及预后之间的关系。应用多因素Cox回归分析预测不良事件的指标。结果:ACTL6A在宫颈癌癌组织阳性表达率(63.5%)明显高于癌旁组织(27.9%)(P<0.05)。ACTL6A蛋白高表达与宫颈癌的淋巴结转移、组织学分解、TNM分期相关,而与患者年龄、肿瘤大小无关。随访时间3-60个月,宫颈癌癌组织高表达ACTL6A蛋白的患者总生存明显低于低表达的患者(P<0.05);其中淋巴结转移、组织学分级、TNM分期和ACTL6A均是宫颈癌患者预后的独立影响指标。结论:ACTL6A与宫颈癌的发生和进展关系密切,是判断宫颈癌患者预后的重要指标。     

Why MUC16 mutations lead to a better prognosis: A study based on The Cancer Genome Atlas gastric cancer cohort

BACKGROUND MUC16, encoding cancer antigen 125, is a frequently mutated gene in gastric cancer. In addition, MUC16 mutations seem to result in a better prognosis in gastric cancer. However, the mechanisms that lead to a better prognosis by MUC16 mutations have not yet been clarified.AIMTo delve deeper into the underlying mechanisms that explain why MUC16 mutations signal a better prognosis in gastric cancer.METHODSWe used multi-omics data, including mRNA, simple nucleotide variation, copy number variation and methylation data from The Cancer Genome Atlas, to explore the relationship between MUC16 mutations and prognosis. Cox regression and random survival forest algorithms were applied to search for hub genes. Gene set enrichment analysis was used to elucidate the molecular mechanisms. Single-sample gene set enrichment analysis and “EpiDISH” were used to assess immune cells infiltration, and “ESTIMATE” for analysis of the tumor microenvironment.RESULTSOur study found that compared to the wild-type group, the mutation group had a better prognosis. Additional analysis indicated that the MUC16 mutations appear to activate the DNA repair and p53 pathways to act as an anti-tumor agent. We also identified a key gene, NPY1R (neuropeptide Y receptor Y1), which was significantly more highly expressed in the MUC16 mutations group than in the MUC16 wild-type group. The high expression of NPY1R predicted a poorer prognosis, which was also confirmed in a separate Gene Expression Omnibus cohort. Further susceptibility analysis revealed that NPY1R might be a potential drug target for gastric cancer. Furthermore, in the analysis of the tumor microenvironment, we found that immune cells in the mutation group exhibited higher anti-tumor effects. In addition, the tumor mutation burden and cancer stem cells index were also higher in the mutation group than in the wild-type group.CONCLUSIONWe speculated that the MUC16 mutations might activate the p53 pathway and DNA repair pathway: alternatively, the tumor microenvironment may be involved.     

人重组载脂蛋白E在大肠杆菌中的表达和纯化

用含有载脂蛋白EcDNA的PET32a原核表达载体转化大肠杆菌BL21（DE3），使之高效表达载脂蛋白E-thioredoxin融合蛋白，利用融合蛋白上的一段组氨酸序列，用镍离子亲合层析柱进行分离纯化。由于在载脂蛋白E和thioredoxin之间存在凝血酶的识别位点，用凝血酶消化后，经SephacrylS-300凝胶过滤得到人重组载脂蛋白E。用此方法可以从1L大肠杆菌培养液中纯化20-30mg高纯度的各种载脂蛋白E异构体和非自然存原突变体。方法简便，产量高，纯度达95%以上。     

Role of cytochrome epoxygenase (CYP2J2) in the pathophysiology of coronary artery disease in South Indian population

Background

The cytochrome P-450 2J2 (CYP2J2) is known to be one of the major enzymes of epoxygenase pathway of arachidonic acid in extrahepatic tissues, which produces series of regioisomeric cis-epoxyeicosatrienoic acids (EETs) such as 5,6-, 8,9-, 11,12-, and 14,15-EETs. In the present study, we analyzed the impact of a genetic variant in CYP2J2 on coronary artery disease (CAD) in the Telangana region of Indian population.

构建不同筛选特性的HBV X基因真核表达载体

目的:构建不同筛选特性的两个HBV X基因真核表达载体.方法:从质粒pEcob6中PCR扩增HBV X全基因,利用pCEP4和pcDNA3.1( )两者多克隆位点的特点,选用pGEM(R)-T Easy Vector构建中间载体pEasy-X,分别酶切后连接特异性片段构建载体pCEP4-X和pcDNA3.1( )-X.结果:从质粒pEcob6成功PCR扩增出HBV X全基因并克隆至质粒pEasy-X,酶切、PCR及测序均证实真核表达载体质粒pCEP4-X和pcDNA3.1( )-X构建成功.结论:具有不同筛选特性的两个HBVX基因真核表达载体业已成功构建.     

JDP2、Phf2蛋白在非小细胞肺癌组织中的表达及其与病理特征的相关性

目的探讨二聚化蛋白(JDP2)、Phf2蛋白在非小细胞肺癌(NSCLC)组织中的表达水平,及其与病理特征相关性。 方法收集2018年1月至2019年3月我院切除并经病理证实的65例NSCLC标本,其中>肿瘤边缘5 cm的癌旁组织作为空白对照组,收集患者基线资料性别、年龄、BMI、肿瘤直径、分化程度、肿瘤转移、肿瘤分期、病理类型及三年生存情况,采用免疫组化染色法检测JDP2、Phf2蛋白表达量,分析JDP2、Phf2蛋白与NSCLC患者临床病理特征及预后生存期相关性。 结果癌旁组织中JDP2、Phf2阳性表达率高于癌组织中JDP2、Phf2阳性表达率(P<0.05)。采用Spearman值分析两者关联性,结果JDP2、Phf2在NSCLC组织中共同表达呈负相关关系,二者具有协同作用(P<0.05)。分期Ⅲ期、出现肿瘤转移的NSCLC患者JDP2、Phf2阳性表达率低于分期Ⅰ/Ⅱ期、无肿瘤转移NSCLC患者JDP2、Phf2阳性表达率,而分化程度高级的NSCLC患者JDP2、Phf2阳性表达率高于分化程度低级的NSCLC患者JDP2、Phf2阳性表达率(P<0.05)。3年随访期间存活患者42例(64.62%),死亡23例(35.38%)。肿瘤直径>3 cm、TNM分期Ⅲ期、出现肿瘤转移、JDP2阴性、Phf2阴性的NSCLC患者存活率低于肿瘤直径≤3 cm、TNM分期Ⅰ/Ⅱ期、无肿瘤转移、JDP2阳性、Phf2阳性的NSCLC患者(P<0.05)。 结论JDP2、Phf2蛋白在NSCLC组织中均呈低表达,其表达水平与患者肿瘤TNM分期、肿瘤转移及预后呈相关性。